Modelled cost-effectiveness of high cut-off haemodialysis compared to standard haemodialysis in the management of myeloma kidney

References

• Alexander DD, Mink PJ, Adami H, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 2007;120(Suppl. 12):40-61
   PubMed Web of Science ®Google Scholar
• Bladé J, Fernández-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889-93
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000;65:175-81
   PubMed Web of Science ®Google Scholar
• Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999;13:79-90
   PubMed Web of Science ®Google Scholar
• Torra R, Bladé J, Cases AL, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995;91:854-9
   PubMed Web of Science ®Google Scholar
• Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure. Ann Intern Med 2005;143:777
   PubMed Web of Science ®Google Scholar
• Lee C, Zangari M, Barlogie B, et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004;33:823-8
   PubMed Web of Science ®Google Scholar
• Rayner HC, Haynes AP, Thompson JR, et al. Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med 1991;79:517-25
   PubMedGoogle Scholar
• Irish AB, Winearls CG, Littlewood T. Presentation and survival of patients with severe renal failure and myeloma. Q J Med 1997;90:773-80
   Google Scholar
• Magee C, Vella JP, Tormey WP, et al. Multiple myeloma and renal failure: one center's experience. Renal Failure 1998;20:597-606
   PubMed Web of Science ®Google Scholar
• Montseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998;13:1438-45
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604-6
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Roussou M, Gavriatopoulou M, et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009;9:302-6
   PubMedGoogle Scholar
• Innes A, Cuthbert RJ, Russell NH, et al. Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol 1994;16:149-56
   PubMedGoogle Scholar
• Rota S, Mougenot B, Baudouin B, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine 1987;66:126-37
   PubMed Web of Science ®Google Scholar
• Haynes RJ, Read S, Collins GP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2009;25:419-26
   PubMed Web of Science ®Google Scholar
• Cserti C, Haspel R, Stowell C, et al. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007;47:511-14
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18:886-95
   PubMed Web of Science ®Google Scholar
• Zucchelli P, Pasquali S, Cagnoli L, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney International 1988;33:1175-80
   PubMed Web of Science ®Google Scholar
• Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990;150:863-9
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4:745-54
   PubMed Web of Science ®Google Scholar
• Hutchison C, Airia P, Cook M, et al. Improving outcomes in patients with renal failure secondary to multiple myeloma: results from ChAR2M2. In: Blood (ASH Annual Meeting Abstracts). 2009 p. 1875
   Google Scholar
• Hutchison CA, Cook M, Heyne N, et al. European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 2008;9:55
   PubMedGoogle Scholar
• National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal, 2008. Available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Last accessed date 23 July 2009]
   Google Scholar
• Weibull W. A statistical distribution function of wide applicability. J Appl Mech Trans ASMA 1951;18:293-7
   Google Scholar
• UK Department of Health. NHS Costing Manual 2007–2008. 2008. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_082745.pdf [Last accessed date 23 July 2009]
   Google Scholar
• Brouwer W, Rutten F, Koopmanschap M. Costing in economic evaluation. In: Drummond W, McGuire A (eds). Economic Evaluation in Health Care: Merging Theory with Practice. Oxford, UK: Oxford University Press, 2001
   Google Scholar
• Hunink M, Glasziou P, Siegel J, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, UK: Cambridge University Press, 2001
   Google Scholar
• Luce B, Manning W, Siegel J, et al. Estimating costs in cost-effectiveness analysis. In: Gold M, Siegel J, Russell L, Weinstein M (eds). Cost-Effectiveness in Health and Medicine: Report of the Panel on Cost-Effectiveness. New York, USA: Oxford University Press, 1996
   Google Scholar
• Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31
   PubMed Web of Science ®Google Scholar
• Drummond M, Sculpher G, Torrance B, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford, UK: Oxford University Press, 2005
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. CADTH 2006. Guidelines for the Economic Evaluation of Health Technologies, 3rd edn. Canada, 2006. Available at: http://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf [Last accessed date 20 July 2009]
   Google Scholar
• Van Agthoven M, Segeren CM, Buijt I, et al. A cost–utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma: a prospective randomised phase III study. Eur J Cancer 2004;40:1159-69
   PubMed Web of Science ®Google Scholar
• Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney International 2005;68:2801-8
   PubMed Web of Science ®Google Scholar